^
Association details:
| Biomarker: | HGF elevation |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Regimen: | FOLFIRINOX (5-fluorouracil + irinotecan + leucovorin calcium + oxaliplatin) |
| Direction: | Resistant |
Evidence:
Source:
Title:
The use of elevated circulating hepatocyte growth factor (HGF) level as a potential prognostic biomarker in locally advanced pancreatic cancer.
Published date:
01/11/2021
Excerpt:
This was an analysis of plasma HGF in patients enrolled in a single arm phase II study (NCT01821729) of patients with previously untreated locally advanced pancreatic ductal adenocarcinoma (PDAC) treated with FOLFIRINOX and losartan....On univariate analysis, elevated HGF was associated with poorer OS (HR 2.28, 95% CI 1.06–4.87, p = 0.03). On multivariate analysis, after controlling for tumor size and baseline CA19-9, elevated plasma HGF remained significantly associated with poorer OS (HR 2.58, 95% CI 1.16–5.70, p = 0.02).
Trial ID:
